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Is Ambient Ethene a Cancer Risk Factor?
M. Tornqvist
Department of Radiobiology, Stockholm University, Stockholm, Sweden
Ethene is, on a molar basis, a major urban air pollutant. It has been shown beyond doubt that a fraction of inhaled ethene is metabolized in mammals
(including humans) via ethylene oxide, an electrophilic reagent that has been shown to be mutagenic and carcinogenic. To the extent that the lineari-
ty hypothesis for dose-response relationships at low levels is accepted, exposure to ethene is therefore expected to lead to a risk increment. In
order to judge whether ethene as a single compound should be considered a risk factor, it has to be evaluated whether this risk increment is negligi-
bly small or of concern to individuals or societies. The magnitude of the cancer risk from ethene cannot be inferred from animal experiments.
Because of saturation of the metabolism of ethene, sufficient statistical power cannot be attained in long-term animal tests with about 100 animals
per dose. By application of the radiation-dose equivalent of the unit of target dose of ethylene oxide and using the best (although still uncertain)
value for the conversion factor (about 5%), exposure to 10 ppb ethene-a level occurring in urban areas-is expected to lead to a lifetime risk of
cancer death amounting to approximately 70 per 100,000. According to a recent estimate the average exposure in Sweden to ethene is some six
times lower. These figures are uncertain by a factor of at least three. They indicate ethene to be a risk factor of concern. - Environ Health
Perspect 102(Suppl 4):157-160 (1994).
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Introduction
The gas phase ofautomotive engine exhausts
and consequently ofpolluted urban air con-
tains a number ofunsaturated hydrocarbons
(i.e., alkenes, alkadienes). Particularly ethene
occurs at relatively high concentrations (1),
some 105 times higher than that of, for
example, benzok[o]pyrene. Alkenes are
known to be metabolized in vivo via epox-
ides, as was first shown for ethene (2-4) and
later for butadiene (4). Because 1,2-epox-
ides are electrophilically reactive and have
been shown to be mutagenic and carcino-
genic (5), the parent alkenes also should be
suspected of being potential environmental
carcinogens. The alkenes ethene (6),
propene (7), and 1,3-butadiene (8) have
been subjected to long-term cancer tests
with rodents, only the latter showing a posi-
tive result.
The reason why a carefully conducted
cancer test with ethene in the Fischer 344
rat did not show any change of the tumor
incidence may be attributed to saturation of
the metabolism, limiting the ethylene oxide
dose achievable to approximately one-fourth
of the dose that would permit detection, at
reasonable statistical power, of raised cancer
incidence in a test with some 100 animals
(Figure 1) (9,10). The positive response to
butadiene probably is because ofpartial for-
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mation also of diepoxybutane, the muta-
genic and carcinogenic effectiveness of
which is greater than that of the monooxi-
ranes bysome two orders ofmagnitude (5).
This paper summarizes efforts to elucidate
the question: To what extent is ambient
ethene to be considered a risk factor ofcon-
cern? This approach thus illustrates the
quantitative aspect of risk identification, a
risk-management function that is qualitative
in principle (11).
The previously mentioned inability of
ethene to provoke a significant increase in
cancer tests ofconventional scope might at
first sight be taken to indicate that the com-
pound is innocuous. In view of the low
resolving power of cancer tests, however,
this is not necessarily true. Considering
that the metabolite, ethylene oxide, is
judged to be a probable human carcinogen
(12), it has to be investigated whether the
cancer risk associated with ambient con-
centrations of ethene, in urban environ-
ments mostly at parts per billion levels, is
ofnonnegligible magnitude.
Because it has not been possible to extrap-
olate the riskofethene from animal testdata,
other ways must be sought out. These must
comprise in vivo dose measurement ofethyl-
ene oxide, the reactive metabolite, and estab-
lishment ofthe relationship between in vivo
dose and risk. In the presentstudy, the latter
has been done bydetermination ofthe radia-
tion-dose equivalent (rad-equivalent) of a
unit of chemical dose, given as millimolar-
hour (mMhr), the dose defined as the inte-
gral over time of concentration (13).
Besides development of a technique for in
vivo dose monitoring, a number of ques-
tions concerning person-weighted exposure
doses, metabolism in animals and man, etc.,
had to be answered in order to judge
whether ethene should be considered a risk
factor. The rad-equivalent approach appears
to be useful for the identification and esti-
mation of risks from many environmental
genotoxic chemicals for which disease-epi-
demiological or cancer-test data are unavail-
able (14). Monitoring ofthe in vivodose of
a reactive chemical or its metabolites is
based on the measurement ofreaction prod-
ucts with (adducts to) macromolecules in
tissues. This association ofriskwith a chemi-
cal end point increases the sensitivity by sev-
eral orders of magnitude as compared to
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Figure 1. Saturation of the metabolism of ethene
illustrated by the external concentrations of ethylene
oxide (ordinary axis) and ethene (abscissa) that give
the same in vivodose of ethylene oxide. The maximum
approached, 5 ppm, is belowthe detection level (----)






that renders the method generally useful
for risk identification.
Methods
It was early shown by Miller and Miller
(15) that most genotoxic chemicals (i.e.,
cancer initiators and mutagens) are elec-
trophilic reagents or are metabolized to such
reagents. Electrophiles (e.g., alkylating
agents such as epoxides) react with nucle-
ophilic atoms in DNA, the target for biolog-
ical effects. Reaction products with nucle-
ophilic atoms (S, N, 0) in other macromol-
ecules, especially certain amino acids in
proteins, are parallelly formed.
Determination of adducts to DNA and
proteins offers a means ofidentifying geno-
toxic risk factors in vivo. Hemoglobin (Hb)
has been found suitable as a monitor mole-
cule because it is accessible in large amounts
and because Hb adducts have a long, well-
defined life-span and can be identified
chemically by available methods. Tissue
doses useful for risk estimation can be cal-
culated from levels ofHb adducts (16).
Hb adduct monitoring was shown to be
useful for risk identification and risk esti-
mation, but the lack of a sensitive, rapid,
and reproducible analytical method limited
applications. For this reason, a large effort
was put into the development of a new
method for Hb adduct analysis with a sen-
sitivity sufficient for applications connected
with urban air pollution.
The nitrogen in the N-terminal amino
acids, valines, in the two a- and 5-chains in
Hb, is a major reaction site for epoxides and
other alkylating agents (16). This was one
reason to try the Edman sequencing tech-
nique for isolation ofHb adducts. When this
procedure was applied to [14C]ethylene
oxide-alkylated globin, it was observed (17)
that radioactive material could be extracted
already from the weakly alkaline coupling
medium in which the protein is treated with
the Edman reagent. This work resulted in a
procedure, the N-alkyl Edman method
(18,19), in which globin samples are deriva-
tized with pentafluorophenyl isothiocyanate
in formamide. Alkylated N-terminal valines
are then extracted as pentafluorophenylthio-
hydantoins, which, following purification
steps, are analyzedwith high sensitivity bygas
chromatography-mass spectrometry with




Aproblem ofbasic importance in risk assess-
ment of ethene is the relationship between
exposure dose ofethene and dose in tissues
of the ultimate carcinogen, ethylene oxide.
In an early phase ofthis work, this ratio was
established in animal models.
Segerback (3) measured, by means of
Hb adducts, doses in mice that were com-
patible with 8% of inhaled ethene being
metabolically converted to ethylene oxide.
In this work, radiolabeled ethene was used,
and from the level ofDNA adducts in vari-
ous tissues, it was concluded that the dose
was approximately the same in different
parts of the body. This means that the
measured blood dose is relevant to the tar-
get dose in various organs. T6rnqvist et al.
(19) used the N-alkyl Edman method to
determine in vivo doses of ultimate car-
cinogens from alkenes in hamsters and rats
exposed to automotive engine exhausts.
Through the determination of N-(2-
hydroxyethyl) valine (HOEtVal), the
adduct formed in the reaction of ethylene
oxide with N-terminal valine, it was found
that 5 to 10% of inhaled ethene in the
exhaust was metabolized to ethylene oxide.
The uncertainty in the determination was
mainly due to difficulties in correctly
assessing time-weighted average exposure
concentrations. The exposures were car-
ried out with diesel exhaust, with and with-
out particle filter, three and two doses,
respectively; and with gasoline exhaust,
with and without catalyst, at two doses.
Adduct levels were shown to be linearly
dependent on exposure level. When a cat-
alytic converter was used, the adduct levels
in animals exposed to gasoline exhaust were
strongly reduced in agreement with the
reduced ethene exposure.
Although these experiments showed
approximately the same rate of conversion
ofinhaled ethene to ethylene oxide in three
animal species and thus invites to extrapo-
lation to other species, it was considered
important to prove that ethene is metabo-
lized in the same way in man.
The conversion of ethene to ethylene
oxide in humans has been studied in ciga-
rette smokers; a steady-state adduct incre-
ment has been shown amounting to about
8 pmole HOEtVal/g globin/smoked ciga-
rette and day (20,21), a value confirmed
by Bailey et al. (22) using a modification
of the N-alkyl Edman method. A conclu-
sion from these studies is that about 6% of
about 0.25 mg ethene in the mainstream
smoke from each cigarette is converted to
ethylene oxide. Studies of persons with
occupational exposure to ethene e.g., fruit-
store workers (23) and plastics industry
workers (Tornqvist et al., unpublished
material), show values in the range of 1 to
10% conversion. This uncertainty is mainly
due to difficulties of correctly assessing the
exposure to ethene. For that reason, human
inhalation studies with controlled exposure
have been conducted with results indicating
about 2% conversion but a three times
longer half-life in vivo of ethylene, i.e., in
support ofthe in vivo dose per inhaled mil-
ligram of ethene as concluded from the
smoker study (manuscript in preparation).
In a pharmacokinetic study in humans,
Shen et al. (24) found about 4% ofinhaled
ethene to be metabolized in the body.
The previously mentioned judgments
were based on dose monitoring in persons
occupationally exposed to ethylene oxide,
where the steady-state level of HOEtVal
was found to be 2.4 nmoles/g globin dur-




The present version of the N-alkyl Edman
method is sufficiently sensitive to measure
adduct levels down to a fewpmole per gram
globin (i.e., the increments expected to be
associated with chronic exposure to a few
parts per billion ofethene). Such measure-
ments, however, are obscured by the exis-
tence ofa background level ofHOEtVal in
Hb. In addition, epidemiological studies of
the variation ofthe adduct level have not yet
been carried out on populations sufficiently
differing in degree ofurbanization (26,21).
The background varies in the range from
8 to 25 pmole HOEtVal/g globin and has
been found in animal experiments to be
partly caused by ethene formation from
food and intestinal bacteria (27). In mea-
surements ofethene exhaled by humans, it
was confirmed that endogenously formed
ethene is the main source of the back-
ground HOEtVal level (28), allowing for a
small contribution (about 5 pmole/g glo-
bin) from urban air and/or passive smoking
(29). It has also been shown that at these
low levels artifact formation of HOEtVal
during storage ofHb samples must be pre-
vented (30).
Measurement of ethene at four sites in
Stockholm 1987 (31) showed average levels
around 25 ppb in areas with heavy traffic.
As average exposure doses for urban areas
or the whole country had not been deter-
mined at that time and HOEtVal measure-
ments because of the background gave too
uncertain information, the time-weighted
average levels of ethene were estimated
indirectly via carboxyhemoglobin incre-
ments in urban citizens (32,33). These
deliberations were compatible with an aver-
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age ethene exposure to the Swedish popula-
tion in the range 10 to 20 ppb. Although
this level may still occur in very urbanized
areas, the average exposure level in Sweden
was recently estimated to about 1.5 ppb
(see below). An ethene concentration of 10
ppb, a reasonable value in urban areas, is
expected to give an incremental adduct level
of4 pmole HOEtVal/g globin. Because of
the variable background, an increment of
this size could be well determined only in
very large populations. In Table 1, the esti-
mated average increments of HOEtVal
from various sources of ethylene oxide and
ethene have been compiled.
Discussion
In the rad-equivalence approach, the dose of
acute y- or X-radiation, which produces the
same frequency ofmutation (or other geno-
toxic changes) as 1 mMhr of a chemical
under study is determined. This approach is
based on the unproved but reasonable
assumption that an initiated cell has the
same chance ofgiving rise to a tumor, irre-
spectively of whether it was initiated by a
mutagenic chemical or by low-linear energy
transfer radiation, chosen as reference stan-
dard because it is the environmental factor
that is best investigated with respect to dose-
risk relationships. A comparison of this
kind (ofa genotoxic chemical with ionizing
radiation) is facilitated by the fact that at
low doses the effects ofboth types ofagents
may be fitted to linear dose-response curves.
Through this approach influences ofpromo-
tive and cocarcinogenic conditions prevail-
ing in human populations are implicitlyesti-
mated and allowed for (14).
In a broad range oftest systems, 1 mMhr
of ethylene oxide gives approximately the
same response as 80 rad (0.8 Gy) ofy-radi-
ation (34). Data from the various studies
Table 1. Estimated average increment on N-(2-hydroxyethyl)valine (HOEtVal) in hemoglobin from different




average 1 ppm, 40 hr/week 2400 (25)
Ethene, time-weighted
average 1 ppm, 40 hr/week 100 (21)
Ethene in tobacco smoke,
10 cigarettes/day 85 (21)
Urban air pollution, 10 ppb ethene,
168 hr/week 4a (21)
Background in nonsmokers,
mainly endogenous ethene production 8-25 (21)
a Estimated.
of uptake and metabolism of ethene and
ethylene oxide are further compatible with
ethene giving an in vivo dose of ethylene
oxide, which is about 5% of the dose
received following direct inhalation ofeth-
ylene oxide. The dose received by person-
nel occupationally exposed to ethylene
oxide has been estimated to correspond to
20 rad-equivalent/year ppm, with 1600 hr
exposure per year (25).
From these data, the rad-equivalent ofthe
annual dose of ethylene oxide from ethene
at an ambient concentration of 10 ppb is
calculated to be about 0.05 rad-equivalent
peryear.
The cancer risk associated with an expo-
sure to 10 ppb ethene would thus be about
one-half of the risk because of background
radiation (about 0.1 rad/year). An analysis
ofvarious data indicates that at low-dose rate
the risk may be some four times lower (35)
than has been estimated by the National
Research Council (36). According to this,
the lifetime cancer mortality risk at 10 ppb
ethene would be approximately 7 x 10
Recent figures (35,37) indicate the average
ethene level in Sweden to be 1.8 pg/m3
(approximately 1.5 ppb). This would
mean an average lifetime risk in Sweden
(8.4 million) of 1 x 10 , corresponding to
some 13 cancer deaths and about twice as
many cases ofdisease annually in the coun-
try (35). These figures for the conse-
quences of today's ethene exposure are
thus some five times lower than the ones
estimated to be valid 10 years ago. They
might, if ethene were the sole urban air
pollutant because ofthe evaluation philoso-
phy chosen, be considered close to the
lower limit ofunacceptability.
This identification of ethene as a risk
factor calls for two kinds ofaction: A more
accurate estimation of the magnitude of
this risk, which, given the exposure level
assumed here, has to be considered uncer-
tain by at least a factor three; and measures
to be taken, such as catalytic conversion in
fuel burning, for reduction ofthis risk.
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